Neuropeptide Y is a physiological substrate of fibroblast activation protein: Enzyme kinetics in blood plasma and expression of Y2R and Y5R in human liver cirrhosis and hepatocellular carcinoma

@article{Wong2016NeuropeptideYI,
  title={Neuropeptide Y is a physiological substrate of fibroblast activation protein: Enzyme kinetics in blood plasma and expression of Y2R and Y5R in human liver cirrhosis and hepatocellular carcinoma},
  author={P. F. J. Wong and Margaret G. Gall and William W. Bachovchin and Geoffrey W McCaughan and Fiona M. Keane and Mark D. Gorrell},
  journal={Peptides},
  year={2016},
  volume={75},
  pages={80-95}
}

Figures and Tables from this paper

Identification of Novel Natural Substrates of Fibroblast Activation Protein-alpha by Differential Degradomics and Proteomics*
TLDR
This study greatly expands the repertoire of FAP substrates and shows that FAP has a role in coagulation in the mouse and provides insight into the physiological and potential pathological roles of this enigmatic protease.
Fibroblast activation protein enzyme deficiency prevents liver steatosis, insulin resistance and glucose intolerance and increases fibroblast growth factor-21 in diet induced obese mice
TLDR
This is the first study to show that specific genetic ablation of FAP activity or protein protects against DIO-driven glucose intolerance, hyperinsulinaemia, insulin resistance, hypercholesterolaemia and liver steatosis in mice and provide mechanistic insights.
Fibroblast activation protein (FAP) as a novel metabolic target
The pro‐fibrotic role of dipeptidyl peptidase 4 in carbon tetrachloride‐induced experimental liver injury
TLDR
The data suggest that DPP4 is pro‐fibrotic in CCl4‐induced liver fibrosis and that the mechanisms of DPP 4 pro-f fibrotic action include energy metabolism, B cells, NK cells and CD4+ cells.
Circulating FGF21 Levels in Human Health and Metabolic Disease.
  • M. Keuper, H. Häring, H. Staiger
  • Biology, Medicine
    Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
  • 2019
TLDR
The emerging field of inactivating FGF21 in human blood by fibroblast activation protein (FAP) and its potential clinical implications are discussed, focusing primarily on obesity and obesity-associated diseases such as type-2 diabetes.
Serum Exosomal lncRNA AC007099.1 Regulates the Expression of Neuropeptide-Related FAP, as a Potential Biomarker for Hepatocarcinogenesis
TLDR
Enrichment analysis suggests that the AC009099/miR-7152/FAP ceRNA regulatory network is associated with neuropeptide functional pathways, which may serve as a potential target for the treatment of hepatocellular carcinoma.
Circulating fibroblast activation protein activity and antigen levels correlate strongly when measured in liver disease and coronary heart disease
TLDR
Circulating fibroblast activation protein (cFAP) activity and antigen levels were higher in men and significantly associated with body mass index and EDTA plasma as compared to the levels in citrated plasma from the same healthy individuals.
...
1
2
3
...

References

SHOWING 1-10 OF 58 REFERENCES
Neuropeptide Y, B‐type natriuretic peptide, substance P and peptide YY are novel substrates of fibroblast activation protein‐α
TLDR
The first natural substrates of FAP dipeptidyl peptidase activity are reported, indicating potential roles in cardiac function and neurobiology and furthers the understanding of this unique protease.
Fibroblast activation protein: A cell surface dipeptidyl peptidase and gelatinase expressed by stellate cells at the tissue remodelling interface in human cirrhosis
TLDR
The expression of FAP is delineated in cirrhotic human liver and recombinant FAP was shown to have gelatinase and dipeptidyl peptidase activities and FAP may contribute to the HSC‐induced extracellular matrix (ECM) changes of cirrhosis.
Structural and Kinetic Analysis of the Substrate Specificity of Human Fibroblast Activation Protein α*
TLDR
The first high resolution structure for the apoenzyme as well as kinetic data toward small dipeptide substrates are presented to provide a clear understanding of the molecular determinants responsible for the substrate specificity and endopeptidase activity of FAPα.
Selective Inhibition of Fibroblast Activation Protein Protease Based on Dipeptide Substrate Specificity*
TLDR
These results identify Ac-Gly-BoroPro as a FAP-selective inhibitor and suggest that N-acyl- Gly-Pro-based inhibitors will allow testing of FAP as a therapeutic target.
Antiplasmin-cleaving enzyme is a soluble form of fibroblast activation protein.
TLDR
Data support APCE as a soluble derivative of FAP and Met-alpha2AP as its physiologic substrate, which may increase plasmin inhibition within fibrin surrounding certain neoplasms and have an impact on growth and therapeutic susceptibility.
Relevance of the neuropeptide Y system in the biology of cancer progression.
The peptides pancreatic polypeptide (PP), peptide YY (PYY), and neuropeptide Y (NPY) share a similar structure, known as PP-fold. Within this family of peptides, NPY, a highly conserved 36-aminoacid
Targeted Disruption of Mouse Fibroblast Activation Protein
TLDR
Fap −/− mice are fertile, show no overt developmental defects, and have no general change in cancer susceptibility, to explore the role of FAP in vivo.
Differential gene expression of the three natriuretic peptides and natriuretic peptide receptor subtypes in human liver.
TLDR
Investigation of gene expression of the three NP receptor types as well as of the NP in human liver provides evidence for a local NP system in the human liver.
...
1
2
3
4
5
...